Home > Financial Ratios > GLAND PHARMA

GLAND PHARMA
Core EBITDA Margin

    Back to All Ratios
GLAND PHARMA is part of below Screeners ↓
Top Small Cap Stocks with Best Fundamentals
Top Undervalued Small Cap Stocks
Best 1M Momentum Small Cap Stocks
COMMUNITY POLL
for GLAND PHARMA
Please provide your vote to see the results

GLAND PHARMA Last 5 Year Core EBITDA Margin History

[Consolidated]

Mar2024Mar2023Mar2022Mar2021Mar2020
   Core EBITDA Margin(%) 23.5328.2734.3237.6136.28

What is the latest Core EBITDA Margin ratio of GLAND PHARMA ?

The latest Core EBITDA Margin ratio of GLAND PHARMA is 23.53 based on Mar2024 Consolidated results.
Year Core EBITDA Margin
Mar202423.53
Mar202328.27
Mar202234.32
Mar202137.61
Mar202036.28

How is Core EBITDA Margin of GLAND PHARMA Trending?

Years Core EBITDA Margin % Change
Mar2024 23.53
-16.77
Mar2023 28.27
-17.63
Mar2022 34.32
-8.75
Mar2021 37.61
3.67
Mar2020 36.28 -

Other Financial Ratios of GLAND PHARMA


Compare Core EBITDA Margin ratio of peers of GLAND PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
GLAND PHARMA ₹32,478.0 Cr 7% 12.8% -6.6% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹408,091.0 Cr 2.3% 3.2% 9.5% Stock Analytics
DIVIS LABORATORIES ₹181,302.0 Cr -0.2% 4.5% 49.6% Stock Analytics
CIPLA ₹119,038.0 Cr -0.2% -2% -1.4% Stock Analytics
TORRENT PHARMACEUTICALS ₹117,170.0 Cr 3.7% 6.5% 16.6% Stock Analytics
DR REDDYS LABORATORIES ₹105,061.0 Cr -0% -4.6% -6.2% Stock Analytics


GLAND PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
GLAND PHARMA

7%

12.8%

-6.6%

SENSEX

-1.1%

1%

3.4%


You may also like the below Video Courses